BioSpace News Archive

Zentalis ® Pharmaceuticals, Inc. today announced that on June 3, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 20,000 shares of the Company’s common stock.

BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development.

Avanzanite Bioscience B.V. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending Marketing Authorisation of AKANTIOR® for the treatment of acanthamoeba keratitis in adults and children from 12 years of age.

RELIEF THERAPEUTICS Holding SA today announced that interim Chief Executive Officer Michelle Lock has completed her transitional mandate with the Company.

Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced therapies.

QIAGEN announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States.

Alligator Bioscience announced the publication of positive Phase 2 data on its lead drug candidate mitazalimab in first line metastatic pancreatic cancer in The Lancet Oncology.

Orion is participating in a project led by the University of Turku for which Business Finland recently granted 11.7M€ funding.

QurAlis Corporation announced that it has entered into an exclusive license agreement with Eli Lilly and Company in which QurAlis is granting Lilly global rights to develop and commercialize QRL-204, a potentially best-in-class splice-switching antisense oligonucleotide designed to restore UNC13A function in amyotrophic lateral sclerosis, frontotemporal dementia, and other neurodegenerative diseases.

IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, presented encouraging preliminary clinical data of INB-200 at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago on June 1, 2024.